Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRajib ShomeMSMehmet SamurKGKathleen Gallagher

Discussion

Loading...

Member takes

Overview

Exploratory analysis reveals cilta-cel improves survival outcomes in patients with relapsed multiple myeloma, suggesting potential for wider use in therapy sequencing.

Key Points

  • Cilta-cel treatment resulted in a median progression-free survival of 31 months after prior therapies, showing significant efficacy.
  • Nine patients treated with cilta-cel exhibited a notable response rate, with seven achieving durable responses to therapy.
  • Analysis involved assessing patient outcomes after cilta-cel administration, including toxicity profiles and serum biomarkers.
  • Findings underscore the need for further exploration of salvage therapies like cilta-cel in the treatment of relapsed multiple myeloma.

Cite This Study

Shome et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e124https://doi.org/10.1182/blood-2025-5764
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025
  2. 2CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  3. 3BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  4. 4Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  5. 5Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma2025